Edition:
India

Kaisa Group Holdings Ltd (1638.HK)

1638.HK on Hong Kong Stock

4.22HKD
23 Feb 2018
Change (% chg)

HK$0.08 (+1.93%)
Prev Close
HK$4.14
Open
HK$4.19
Day's High
HK$4.25
Day's Low
HK$4.17
Volume
4,817,426
Avg. Vol
23,907,179
52-wk High
HK$6.91
52-wk Low
HK$2.10

Chart for

About

Kaisa Group Holdings Ltd. is a Hong Kong-based investment holding company principally engaged in property development businesses. The Company operates through five segments. Property Development segment is engaged in the development of residential and commercial properties for sales. Its properties include Shenzhen Woodland... (more)

Overall

Beta: --
Market Cap(Mil.): HK$37,252.05
Shares Outstanding(Mil.): 5,989.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 20.77 16.60
EPS (TTM): -- -- --
ROI: -- 7.23 10.66
ROE: -- 10.74 14.30

BRIEF-Kaisa Group Holdings Says Jan Contracted Sales Was Up 3.8 Pct

* JAN CONTRACTED SALES RMB2,966 MILLION, UP 3.8% Source text for Eikon: Further company coverage:

14 Feb 2018

BRIEF-Kaisa Group Holdings' Yu Jianqing Resigns As An Executive Director

* MAI FAN, EXECUTIVE DIRECTOR OF CO, APPOINTED AS AUTHORISED REPRESENTATIVE OF CO Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

18 Jan 2018

BRIEF-Kaisa Group Holdings ‍Posts Contracted Sales Of About Rmb5,072 Mln In Dec

* ‍CONTRACTED SALES OF APPROXIMATELY RMB5,072 MILLION IN DEC 2017​ Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Kaisa Group Holdings Posts Nov Total Contracted Sales Of About RMB5.10 Bln​

* ‍RECORDED TOTAL CONTRACTED SALES OF APPROXIMATELY RMB5,103 MILLION IN NOVEMBER​

04 Dec 2017

UPDATE 1-China developer Kaisa makes $332 mln investment in biopharma firm

* Developer was China's first to default on offshore bonds (Adds executive comment, Kaisa context, share prices)

29 Nov 2017

BRIEF-Kaisa Group Says Unit To Buy 18.57 Pct Interest In Zhenxing Biopharmaceutical & Chemical Co​

* ‍ANNOUNCES ACQUISITION OF AN APPROXIMATELY 18.57% INTEREST IN ZHENXING BIOPHARMACEUTICAL & CHEMICAL CO​

29 Nov 2017

China's Kaisa to buy 19 pct Zhenxing Bio stake for $332 mln

HONG KONG, Nov 29 Kaisa Group Holdings Ltd said on Wednesday it planned to buy a 2.19 billion yuan ($332 million) stake in blood products producer Zhenxing Biopharmaceutical & Chemical Co Ltd as the Chinese developer diversifies and expands its footprint in the healthcare industry.

29 Nov 2017

BRIEF-Kaisa Group Holdings posts Oct total contracted sales of RMB4,355 mln

* Group recorded total contracted sales of RMB4,355 million in October 2017​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Kaisa Group Holdings announces issue of additional senior notes

* Eentered into subscription agreements for US$30 million 7.25% senior notes due 2020 and US$100 million 7.875% senior notes due 2021

03 Nov 2017

BRIEF-Kaisa Group Holdings updates on total contracted sales for September ​

* ‍Group recorded total contracted sales of about RMB3,211 million in September ​ Source text for Eikon: Further company coverage:

11 Oct 2017

Earnings vs. Estimates